12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Company News  |  Deals

ChipDX, Signal Genetics deal

Signal Genetics will acquire all of ChipDX's assets, including patents for prognostic tests in development for lung, breast and colon caners. Signal also gains ChipDX's web-based interface, which the company said will be used to enhance Signal's physician web portal...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >